{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T15:33:17Z","timestamp":1776526397652,"version":"3.51.2"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,8,11]],"date-time":"2016-08-11T00:00:00Z","timestamp":1470873600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"ESMO MASCC","award":["NOT APPLICABLE"],"award-info":[{"award-number":["NOT APPLICABLE"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1007\/s00520-016-3365-1","type":"journal-article","created":{"date-parts":[[2016,8,10]],"date-time":"2016-08-10T19:52:54Z","timestamp":1470858774000},"page":"289-294","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["2016 updated MASCC\/ESMO consensus recommendations: Prevention of nausea and vomiting following moderately emetogenic chemotherapy"],"prefix":"10.1007","volume":"25","author":[{"given":"Fausto","family":"Roila","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Warr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul J.","family":"Hesketh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Gralla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorn","family":"Herrstedt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karin","family":"Jordan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matti","family":"Aapro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enzo","family":"Ballatori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernardo","family":"Rapoport","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,8,11]]},"reference":[{"key":"3365_CR1","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1007\/s00520-014-2175-6","volume":"22","author":"M Popovic","year":"2014","unstructured":"Popovic M, Warr DG, Deangelis C, et al. (2014) Efficacy and safety of palonosetron for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis of randomized controlled trials. Support Care Cancer 22:1685\u20131697","journal-title":"Support Care Cancer"},{"key":"3365_CR2","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1200\/JCO.2005.04.022","volume":"23","author":"O Geling","year":"2005","unstructured":"Geling O, Eichler HG (2005) Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol 23:1289\u20131294","journal-title":"J Clin Oncol"},{"key":"3365_CR3","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1213\/ane.0b013e318172fa74","volume":"107","author":"C Rojas","year":"2008","unstructured":"Rojas C, Stathis M, Thomas AG, et al. (2008) Palonosetron exhibits unique molecular interactions with the 5-HT3 receptor. Anesth Analg 107:469\u2013478","journal-title":"Anesth Analg"},{"key":"3365_CR4","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1056\/NEJM200005253422102","volume":"342","author":"Italian Group for Antiemetic Research","year":"2000","unstructured":"Italian Group for Antiemetic Research (2000) Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy. N Engl J Med 342:1554\u20131559","journal-title":"N Engl J Med"},{"key":"3365_CR5","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1007\/s00520-003-0488-y","volume":"11","author":"A Inoue","year":"2003","unstructured":"Inoue A, Yamada Y, Matsumura Y, et al. (2003) Randomized study of dexamethasone treatment for delayed emesis, anorexia and fatigue induced by irinotecan. Support Care Cancer 11:528\u2013532","journal-title":"Support Care Cancer"},{"key":"3365_CR6","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1007\/s00520-011-1286-6","volume":"19","author":"PJ Hesketh","year":"2011","unstructured":"Hesketh PJ, Bosnjak SM, Nikolic V, et al. (2011) Incidence of delayed nausea and vomiting in patients with colorectal cancer receiving irinotecan-based chemotherapy. Support Care Cancer 19:2063\u20132066","journal-title":"Support Care Cancer"},{"key":"3365_CR7","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1097\/01.coc.0000145983.35929.2a","volume":"28","author":"C Lindley","year":"2005","unstructured":"Lindley C, Goodin S, McCune J, et al. (2005) Prevention of delayed chemotherapy-induced nausea and vomiting after moderately high to highly emetogenic chemotherapy: comparison of ondansetron, prochlorperazine, and dexamethasone. Am J Clin Oncol 28:270\u2013276","journal-title":"Am J Clin Oncol"},{"key":"3365_CR8","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s00520-009-0680-9","volume":"18","author":"B Rapoport","year":"2010","unstructured":"Rapoport B, Jordan K, Boice JA, et al. (2010) Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study. Support Care Cancer 18:423\u2013431","journal-title":"Support Care Cancer"},{"key":"3365_CR9","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1093\/annonc\/mdv482","volume":"27","author":"C Weinstein","year":"2016","unstructured":"Weinstein C, Jordan K, Green SA, et al. (2016) Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: results of a randomized, double-blind phase III trial. Ann Oncol 27:172\u2013178","journal-title":"Ann Oncol"},{"key":"3365_CR10","doi-asserted-by":"crossref","first-page":"650s","DOI":"10.1200\/jco.2010.28.15_suppl.9057","volume":"28","author":"RJ Gralla","year":"2010","unstructured":"Gralla RJ, Rapoport BL, Jordan K, et al. (2010) Assessing the magnitude of antiemetic benefit with the addition of the NK1 receptor antagonist aprepitant for all platinum agents: analysis of 1872 patients in prospective randomized clinical phase III trials. J Clin Oncol 28:650s abstract 9057","journal-title":"J Clin Oncol"},{"key":"3365_CR11","doi-asserted-by":"crossref","first-page":"107s","DOI":"10.1007\/s00520-013-1991-4","volume":"22","author":"K Jordan","year":"2014","unstructured":"Jordan K, Gralla R, Rossi G, et al. (2014) Is the addition to an NK1 receptor antagonist beneficial in patients receiving carboplatin? Supplementary data with NEPA, a fixed dose combination of netupitant and palonosetron. Support Care Cancer 22:107s abstract 0162","journal-title":"Support Care Cancer"},{"key":"3365_CR12","doi-asserted-by":"crossref","unstructured":"Hesketh PJ, Schnadig ID, Schwartzberg LS, et al. (2016) Efficacy of the neurokinin-1 receptor antagonist rolapitant in preventing nausea and vomiting in patients receiving carboplatin-based chemotherapy. Cancer 122:2418\u20132425","DOI":"10.1002\/cncr.30054"},{"key":"3365_CR13","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1038\/bjc.2013.400","volume":"109","author":"M Tanioka","year":"2013","unstructured":"Tanioka M, Kitao A, Matsumoto K, et al. (2013) A randomized, placebo controlled, double-blind study of aprepitant in nondrinking women younger than 70 years receiving moderately emetogenic chemotherapy. Br J Cancer 109:859\u2013865","journal-title":"Br J Cancer"},{"key":"3365_CR14","doi-asserted-by":"publisher","unstructured":"Yahata H, Kobayashi H, Sonoda K, et al (2016) Efficacy of aprepitant for the prevention of chemotherapy-induced nausea and vomiting with a moderately emetogenic chemotherapy regimen: a multicenter, placebo-controlled, double-blind, randomized study in patients with gynecologic cancer receiving paclitaxel and carboplatin. Int J Clin Oncol 21(3):491\u20137. doi: 10.1007\/s10147-015-0928-y","DOI":"10.1007\/s10147-015-0928-y"},{"key":"3365_CR15","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.lungcan.2014.03.017","volume":"84","author":"Y Ito","year":"2014","unstructured":"Ito Y, Karayama M, Inui N, et al. (2014) Aprepitant in patients with advanced non-small-cell lung cancer receiving carboplatin-based chemotherapy. Lung Cancer 84:259\u2013264","journal-title":"Lung Cancer"},{"key":"3365_CR16","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1007\/s00520-011-1235-4","volume":"20","author":"PJ Hesketh","year":"2012","unstructured":"Hesketh PJ, Wright O, Rosati G, et al. (2012) Single-dose intravenous casopitant in combination with ondansetron and dexamethasone for the prevention of oxaliplatin-induced nausea and vomiting: a multicenter, randomized, double-blind, active-controlled, two arm, parallel group study. Support Care Cancer 20:1471\u20131480","journal-title":"Support Care Cancer"},{"key":"3365_CR17","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/j.ejca.2015.03.024","volume":"51","author":"J Nishimura","year":"2015","unstructured":"Nishimura J, Satoh T, Fukunaga M, et al. (2015) Combination antiemetic therapy with aprepitant\/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy (SENRI trial): a multicenter, randomized, controlled phase III trial. Eur J Cancer 51:1274\u20131282","journal-title":"Eur J Cancer"},{"key":"3365_CR18","doi-asserted-by":"crossref","unstructured":"Molassiotis A, Aapro MA, Dicato M, et al. (2014) Evaluation of risk factors predicting chemotherapy-related nausea and vomiting: results from a European prospective observational study. J Pain Symptom Manage 47:839\u2013848","DOI":"10.1016\/j.jpainsymman.2013.06.012"}],"updated-by":[{"DOI":"10.1007\/s00520-016-3405-x","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2016,9,14]],"date-time":"2016-09-14T00:00:00Z","timestamp":1473811200000}}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-016-3365-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-016-3365-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-016-3365-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T16:27:00Z","timestamp":1498321620000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-016-3365-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,11]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["3365"],"URL":"https:\/\/doi.org\/10.1007\/s00520-016-3365-1","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s00520-016-3405-x","asserted-by":"object"}]},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,11]]}}}